J&J targets generalised myasthenia gravis landscape with nipocalimab
J&J’s BLA was supported by data from the Phase III VIVACITY study, demonstrating the safety and efficacy of biweekly nipocalimab.
J&J’s BLA was supported by data from the Phase III VIVACITY study, demonstrating the safety and efficacy of biweekly nipocalimab.
What's Your Reaction?
